Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

Abstract Background The study aimed to assess 52-week efficacy and safety of secukinumab self-administration by autoinjector in patients with active psoriatic arthritis (PsA) in the FUTURE 3 study (ClinicalTrials.gov NCT01989468). Methods Patients (≥ 18 years of age; N = 414) with active PsA were ra...

Full description

Bibliographic Details
Main Authors: Peter Nash, Philip J. Mease, Iain B. McInnes, Proton Rahman, Christopher T. Ritchlin, Ricardo Blanco, Eva Dokoupilova, Mats Andersson, Radhika Kajekar, Shephard Mpofu, Luminita Pricop, on behalf of the FUTURE 3 study group
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Arthritis Research & Therapy
Subjects:
Psoriatic arthritis
Secukinumab
Autoinjector
Interleukin-17a
FUTURE 3 study
Online Access:http://link.springer.com/article/10.1186/s13075-018-1551-x

Internet

http://link.springer.com/article/10.1186/s13075-018-1551-x

Similar Items